Health Canada authorizes Moderna's flu and combined flu-COVID vaccines for adults 50+

Health Canada has granted authorizations for Moderna's mFLUSIVA, an mRNA influenza vaccine, and mCOFLU, a combined influenza and COVID-19 vaccine, for adults 50 years of age and older. The approvals follow earlier authorizations of the mRNA flu shot in the United States and the combination jab in Europe, making Canada the first nation to approve both products.

Moderna CEO Stéphane Bancel said the dual authorizations represent a step forward for mRNA technology in seasonal respiratory vaccination. The company said it will work with Canadian health authorities and immunization partners to determine when the vaccines will become available.

A Moderna spokesperson told Global News that the new flu shot and combination vaccine will not be included in the 2026-2027 immunization season. Experts note that mRNA-based vaccines can be more effective than traditional vaccines, which rely on microbial proteins or inactivated microbes. The Vanderbilt University Medical Center explains that after injection, cells produce the target protein from the mRNA and display it on their surface.

The National Advisory Committee on Immunization continues to recommend the non-mRNA flu vaccine for all Canadians six months and older this year, with a higher-dose version advised for adults 65 and older. The committee also strongly advises COVID-19 vaccination for individuals 65 and older and residents of long-term care facilities.